CTSO 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• ●Total revenue was $18.5 million for the six months ended June 30, 2026, an increase of $0.2 million, or 0.8%, compared to the prior year. For the three months ended June 30, 2026, total revenue was $9.6 million, an increase of 0.2%.

• ●Gross profit was $13.2 million for the six months ended June 30, 2026, an increase of $0.2 million, or 1.2%, compared to the prior year. Gross margin was 71.2% for the six months ended June 30, 2026, compared to 71.0% in the prior year. Gross profit for the three months ended June 30, 2026, was $7.…

• ●Loss from operations improved by 24% to approximately $5.7 million, from $7.5 million for the six months ended June 30, 2026, and 2025, respectively. For the three-month ended June 30, 2026 and 2025, loss from operations improved by 27% to approximately $2.6 million.

• ●Operating cash burn decreased to $0.4 million for the second quarter and $1.8 million for the six months ended June 30, 2026, compared to $1.4 million and $4.9 million for the three and six months ended June 30, 2025, respectively. The decrease is primarily due to improved operating margins and the…

• For the three months ended June 30, 2026, we generated total revenue of approximately $9.6 million, which is in line with revenues for the three months ended June 30, 2025, of $9.6. million. Revenue performance was led by increases in our distributor and strategic partner territories and direct sale…

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures.

• ●Total revenue was $8.9 million for the three months ended March 31, 2026, an increase of $0.1 million, or 1.6%, compared to the prior year.

• ●Gross profit was $6.1 million for the three months ended March 31, 2026, a decrease of $0.1 million, or 1.2%, compared to the prior year. Gross margin was 69% for the three months ended March 31, 2026, compared to 71% in the prior year.

• ●Loss from operations improved by 21.7% to approximately $3.0 million, from $3.9 million for the three months ended March 31, 2026, and 2025, respectively.

• Comparison for the three months ended March 31, 2026 and 2025:

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• No director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408 during the quarter ended June 30, 2026.

• On June 29, 2026, the Company received a letter from the Staff of Nasdaq that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) because the Company’s minimum MVLS was below the Nasdaq MVLS Requirement of $35 million. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq ha…

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• The Board of Directors of the Company has set the date of the Company’s 2026 Annual Meeting of Stockholders (“Annual Meeting”) to August 13, 2026. The exact time and place of the 2026 Annual Meeting will be specified in our Notice of 2026 Annual Meeting and related proxy statement for the 2026 Annua…

• Because the date of the 2026 Annual Meeting is more than 30 days from the first anniversary of our 2025 Annual Meeting, there is a new deadline for the receipt of any stockholder proposals submitted for the 2026 Annual Meeting. If a stockholder desires to present a proposal for inclusion in our prox…

• No director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408 during the quarter ended March 31, 2026.